Hydroxychloroquine Sulfate
Brand Names: Plaquenil, Sovuna
Methodology & AI Transparency ⓘ
Hydroxychloroquine Sulfate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Malaria Hydroxychloroquine Sulfate Tablets are indicated for the treatment of uncomplicated malaria due to P.
- 2 Real-world patient consensus: 88% patient "Worth It" rating across 10 anonymous logs for Hydroxychloroquine Sulfate (RxNorm 979092).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $6.96 wholesale mail-order against $34.50 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Hydroxychloroquine Sulfate): nausea (8.7%), headache (8.3%), dizziness (5.7%).
Ask our AI Specialists anything about Hydroxychloroquine Sulfate
Hydroxychloroquine Sulfate Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Malaria Hydroxychloroquine Sulfate Tablets are indicated for the treatment of uncomplicated malaria due to P. falciparum, P. malariae, P. ovale , and P. vivax. Hydroxychloroquine Sulfate Tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria Hydroxychloroquine Sulfate Tablets are not recommended for the treatment of complicated malaria. Hydroxychloroquine Sulfate Tablets are not effective against chloroquine or hydroxychloroquine- resistant strains of Plasmodium species .
CLINICAL PHARMACOLOGY: Pharmacokinetics: Following a single 200 mg oral dose of hydroxychloroquine sulfate tablets to healthy male volunteers, the mean peak blood concentration of hydroxychloroquine was 129.6 ng/mL, reached in 3.26 hours with a half-life of 537 hours (22.4 days). In the same study, the plasma peak concentration was 50.3 ng/mL reached in 3.74 hours with a half-life of 2963 hours (123.5 days). Urine hydroxychloroquine levels were still detectable after 3 months with approximately 10% of the dose excreted as the parent drug. Results following a single dose of a 200 mg tablet versus i.v.
Following administration (200 mg/1 Tablet, Film Coated), Hydroxychloroquine Sulfate achieves Systemic oral bioavailability of roughly 73%–85% following first-pass transit bioavailability and initial pharmacodynamic onset within 1–3 hrs (peak cmax) for hydroxychloroquine sulfate onset, governed by a 537 hours terminal elimination (Hydroxychloroquine Sulfate SPL) terminal half-life through hepatic enzymatic processing and renal clearance proportional to creatinine clearance (hydroxychloroquine sulfate).
Before initiating Hydroxychloroquine Sulfate at 200 mg/1 Tablet, Film Coated, clinical safety checklists rule out contraindications use of hydroxychloroquine sulfate tablets is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.; prior anaphylaxis, angioedema, or severe hypersensitivity to hydroxychloroquine sulfate or hydroxychloroquine sulfate excipients. Logged tolerability patterns center on nausea (8.7% of reports), headache (8.3% of reports), fatigue (5.7% of reports).
Hydroxychloroquine Sulfate may compete for P-gp efflux transport, raising narrow-therapeutic-index digoxin serum levels.
Avoid overlapping antimalarial prescriptions alongside Hydroxychloroquine Sulfate to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Use of hydroxychloroquine sulfate tablets is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Hydroxychloroquine Sulfate or Hydroxychloroquine Sulfate excipients
Logged Side-Effect Incidence (10 Reports)
Hydroxychloroquine Sulfate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hydroxychloroquine Sulfate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the Although the JOQUER trial reported no overall benefit from HCQ in pSS patients, stratification suggests that. Rheumatology international • 2021-09-15 • Phase III Randomized Trial | N = 32 | 88/100 | PMID 34165604 ↗ |
| Can This Approach Help? Inside the Latest Research on Hydroxychloroquine does not affect endotheliopathy or coagulopathy biomarkers in HCQ was not found to modify the longitudinal evolution of angiopoietin-2, P-selectin, or D-dimer in hospitalized patients with COVID-19. Angiogenesis • 2025-12-07 • Phase III Randomized Trial | N = 145 | 82/100 | PMID 41353681 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical effectiveness of finasteride versus hydroxychloroquine in the treatment Both finasteride and hydroxychloroquine are equally effective, safe, and well-tolerable for treating FFA patients. Journal of cosmetic dermatology • 2024-02-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 37691183 ↗ |
| Can This Approach Help? Inside the Latest Research on Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: A total of 68 HCWs met the eligibility criteria were randomly allocated to receive HCQ (n = 36) or not (n = 32). BMC research notes • 2023-02-28 • Phase III Randomized Trial | N = 36 | 82/100 | PMID 36849996 ↗ |
| Can This Approach Help? Inside the Latest Research on An open-label randomized controlled trial evaluating the efficacy of In patients with severe COVID-19, the use of chloroquine/hydroxychloroquine added to standard treatment resulted in a significant worsening of clinical status, an increased risk of kidney dysfunction and an increased need for... Scientific reports • 2021-04-27 • Phase III Randomized Trial | N = 105 | 82/100 | PMID 33907251 ↗ |
Hydroxychloroquine Sulfate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1441/unit (~$4.32/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $6.96 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $8.00 / mo | View logs ↓ |
Hydroxychloroquine Sulfate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Hydroxychloroquine Sulfate RxNorm Concept ID | 979092 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1441 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $6.96 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 88.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Hydroxychloroquine Sulfate Patient Community, Cohort Filters & Dosage Logs
Deterministic Hydroxychloroquine Sulfate reference combining NIH RxNorm (979092), Medicaid NADAC ($0.1441/unit), and anonymous cohort outcomes (88% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Hydroxychloroquine Sulfate community threads and patient logs by age, biological sex, dosage, and treatment duration.